Angiotensin II accelerates and renin angiotensin system blockade halts progression; blockade with high doses even reverses established glomerulosclerosis. Aldosterone also accelerates progression of glomerulosclerosis, partially independently of angiotensin II. It was the aim of this study to assess the relative ability of an angiotensin receptor type 1 (AT 1 ) blocker, a mineralocorticoid receptor blocker and their combination to reverse glomerulosclerosis. Sprague-Dawley rats were subjected to subtotal renal ablation (SNX) or sham operation. Eight weeks after surgery they were either sacrificed or allocated to treatment with vehicle, losartan, spironolactone, their combination, or unspecific antihypertensive treatment (dihydralazine) for 4 weeks. Renal morphology was evaluated by stereology in tissues obtained using pressure-controlled perfusion fixation. Systolic blood pressure was 
Introduction
Glomerulosclerosis and interstitial fibrosis tend to progress over time even if the primary insult to the kidney is no longer operative (11) . Blocking the renin-angiotensin system (RAS) with angiotensin converting enzyme (ACE) inhibitors or angiotensin type 1 receptor (AT 1 ) blockers slows progression in various experimental models and in patients with chronic kidney disease (11) . In humans the possibility to reverse established glomerular lesions was clearly demonstrated in diabetic nephropathy after isolated pancreatic transplantation (7) . In the renal ablation model of the rat reversal of glomerulosclerosis was seen after administration of high dose ACE inhibitors or AT 1 blockers (2, 8, 16) . In this model aldosterone accelerated progression of glomerulosclerosis independent of angiotensin II (ANG II) (10, 13) . This finding is clinically relevant because frequently during prolonged treatment with ACE-inhibitors or AT1 blockers "aldosterone breakthrough" occurs, i.e. a delayed increase of aldosterone concentration after an initial fall following pharmacological blockade of the RAS (24).
It was the purpose of this study to compare the ability of the angiotensin receptor type 1 blocker losartan, the mineralocorticoid receptor blocker spironolactone and their combination to reverse established glomerulosclerosis.
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Material and Methods
Animals
All animal procedures were approved by the local ethic committee for animal experiments. Male Sprague-Dawley rats weighing 344±81 g were obtained from Charles River (Sulzfeld, Germany) at the age of 8 weeks. The animals were housed at constant room temperature (21±1°C) and humidity (75±5%) and were exposed to a 12 h light on, 12 h light off cycle. The animals received a standard rodent diet ad libitum (ssniff R/M-H; Ssniff, Germany) containing 19% protein, 41% carbohydrates, 3.3% fat, 0.24% sodium, and 0.92% potassium. After a 1-week adaptation period the animals were randomly allotted to undergo two-step subtotal nephrectomy (SNX), or sham operation respectively as described before (1).
After the operation all the animals were followed for 8 weeks without additional intervention.
After that period one group of animals was sacrificed and the remaining animals were randomized to receive no treatment or treatment with losartan (MSD Chibropharm, Haar, Germany, 250 mg/kg body weight/day in the drinking water), with spironolactone (Aldactone, Hoffmann-LaRoche, Grenzlach-Wyhlen, Germany, 15 mg/kg body weight/day in the drinking water), with the combination of losartan plus spironolactone (in the same doses) or with the nonspecific antihypertensive dihydralazine (Nepresol, Teofarma, Pavia, Italy, 20 mg/kg body weight/day in the drinking water) for the subsequent 4 weeks. The dose of spironolactone was selected after a pilot study in which 80% of animals had died on spironolactone 80 mg/kg (and 30% on 30 mg/kg) in combination with high dose losartan. Daily water consumption was monitored, and the concentrations of losartan, spironolactone and dihydralazine were adjusted to maintain a stable daily dose. The following groups were studied: Body weight and systolic blood pressure (by tail pletysmography) were measured at regular intervals. At week 4, 7, and 12 animals were kept in metabolic cages for 24-h urine collection.
Albumin excretion.
Urinary albumin excretion was measured using ELISA technique and rat-specific rat anti-albumin antibodies as described previously (2) .
Perfusion fixation and tissue sampling
The experiment was terminated 8 or 12 weeks after the surgery under general anesthesia (100 mg/kg ketamine hydrochloride [Ketamin 10%; Essex Tierarznei, Germany] and 3.0 mg/kg xylazine [Xylazin 2%; Ceva Tiergesundheit, Germany]). Abdominal aorta was catheterized, blood samples were taken and retrograde perfusion fixation was performed using 3% glutaraldehyde solution at body temperature for morphologic investigations or ice-cold NaCl for immunohistochemistry and Western blotting, respectively (21) . The perfusion pressure was kept constant at 120 mmHg. The kidneys were weighed and dissected in a plane perpendicular to the interpolar axis, yielding slices of 1-mm width. Tissue samples were embedded in paraffin; 3 µm sections were prepared and stained with PAS. Five small pieces of one kidney were selected by area weighted sampling and embedded in Epon-Araldite from which semithin sections (0.5 µm) were prepared and stained with methylene-blue and basic fuchsin. For immunohistochemical investigations tissues were fixed in 4% formalin, and embedded in paraffin to obtain 3 µm sections. For Western blotting samples were snap-frozen in liquid nitrogen and stored at -80ºC until analysis.
Morphologic Investigations
All morphological investigations were performed in a blinded manner by an observer who was unaware of the study protocol. For the glomerulosclerosis index the degree of sclerosis within the glomerular tuft was determined on PAS-stained paraffin sections at a magnification of ×400, using the semiquantitative scoring system proposed by El Nahas et al (6) . The score of each animal was derived as the mean of 100 glomeruli. The indices of tubulointerstitial and vascular damage were also assessed at a magnification of ×100 using similar scoring systems (2).
The number of glomeruli per kidney and mean glomerular volume were determined using the point counting method as previously described (21) . Capillaries and the number and volume of glomerular cells were analyzed in semithin sections at ×1000 magnification using the point counting method as previously described (21) .
Immunohistochemistry
Immunohistochemistry was performed using formalin-fixed paraffin-embedded sections with the antibodies against: collagen type IV (Biotrend, Germany), desmin (Dako, Germany), NF B, TGF-1, VEGF (SantaCruz Biotechnologies, Germany), VEGF receptor 2 (Abcam, UK). Primary antibody was applied for 1 hour at room temperature, followed by a The sections were examined under light microscopy at ×400 magnification using a semiquantitative scoring system (0 to 4): 0=no expression, 1=mild expression, 2=moderate expression, 3=strong expression, and 4=very strong expression. The number of podocytes per glomerulus staining positively for desmin was determined.
Western Blotting
Samples of kidney cortex were homogenized and the protein concentration was determined according to Bradford method (Bio-Rad, Germany). An amount of 100µg protein was electrophoresed on SDS-polyacrylamide gels. Subsequently proteins were electroblotted onto polyvinyldifluoride membranes (Immobilon-P, pores 0.45µm, Millipore, Germany). The membranes were blocked with 5% non-fat dry milk in tris-buffered saline with 0.5% Tween 20 (TBS-T) and incubated for 2 h at room temperature with the primary antibody againstsmooth muscle actin (Sigma, Germany), TGF-1 (SantaCruz Biotechnologies, Germany).
A horseradish peroxidase-conjugated secondary antibody (SantaCruz Biotechnology, Germany) was used. Peroxidase labelling was detected according to the manufacturer's recommendations (GE Healthcare, UK). To control for variations in protein loading or transfer, membranes were washed and re-incubated with anti--actin antibody (Abcam, UK).
Exposed films were scanned with an imager (Herolab, Germany) and the data were analyzed using computer software (EASY Win 32, Herolab, Germany).
Statistical analysis
Data are given as mean ± SD. For Western blots the vehicle treated sham-op group served as reference and the mean value of individual measurements was set as 100%. The value for each animal was expressed as manifold of reference. After testing for normal distribution the Kruskal-Wallis test or one-way analysis of variance (ANOVA) were chosen, followed by Duncan's multiple-range test for differences between groups. The results were considered significant when the probability of error (P) was lower than 0.05.
Results
Animal data
As shown in table 1 at baseline and at the end of the study body weight did not differ between the SNX groups. The weight of the left kidney remnant was significantly higher in untreated SNX, SNX + spironolactone, and SNX + dihydralazine compared to the intact left kidney weight in sham-op. Plasma urea and creatinine concentrations were significantly higher in all SNX groups compared to sham-op, and no difference was noted between the treatments.
The serum potassium concentration of SNX animals was not altered by any of the treatments (table 1). Serum aldosterone concentration was significantly higher in untreated SNX at week 12 compared to sham-op and untreated SNX at week 8 (table 1) . At week 12 it was significantly lower in SNX + losartan and SNX + losartan + spironolactone compared to untreated SNX.
Systolic blood pressure
Systolic blood pressure was significantly higher in all SNX groups compared to sham-op from week 4 through 8. Delayed treatment with losartan, spironolactone, losartan + spironolactone, or dihydralazine significantly decreased blood pressure in SNX animals ( fig.   1 ). No significant differences in BP were noted between the treatments.
Urinary albumin excretion rate.
Urinary albumin excretion rate was significantly higher in SNX animals compared to sham-op at week 8 and increased further in untreated SNX, SNX treated with spironolactone, and SNX treated with dihydralazine at week 12 ( fig. 2 ). In SNX animals treated with losartan alone or in combination with spironolactone albumin excretion decreased between week 8 and 12 and was not significantly different from sham-op at week 12.
Indices of glomerulosclerosis, tubulointerstitial and vascular damage
Indices of glomerulosclerosis (GSI), tubulointerstitial (TII), and vascular (VI) damage were significantly higher in all SNX groups compared to sham-op. GSI was significantly higher in untreated SNX and SNX + dihydralazine at week 12 compared to SNX at week 8 ( fig. 3, 4) . Treatment with losartan alone or in combination with spironolactone resulted in significantly lower GSI compared to SNX at week 8. No difference in GSI was observed between SNX + spironolactone at week 12 and SNX at week 8 ( fig. 3, 4) .
TII was significantly higher in untreated SNX at week 12 compared to SNX at week 8 ( fig. 3 ). At week 12 TII was significantly lower in SNX treated with losartan, spironolactone, and losartan + spironolactone, respectively compared to untreated SNX and was not significantly different from SNX at week 8. At week 12 TII of SNX treated with dihydralazine was significantly lower than that of untreated SNX, but still significantly higher than that of SNX at week 8.
VI was significantly higher in untreated SNX at week 12 compared to SNX at week 8 and was significantly lower in SNX treated with losartan, spironolactone, losartan + spironolactone, and dihydralazine, respectively compared to untreated SNX at week 12 ( fig.   3 ).
Number and volume of glomeruli, analysis of glomerular cells and capillaries
The total number of glomeruli per kidney was reduced from an average 31401±5899 to 11828±2443 after SNX with little variance between the SNX groups documenting that reduction of nephron number had been precise with little interindividual variation ( fig. 5 ).
The mean glomerular volume was significantly higher in all SNX groups compared to sham-op animals. It was also significantly higher in untreated SNX at week 12 compared to SNX at week 8 ( fig. 5 ). The glomerular volume was significantly lower in SNX animals treated with losartan alone or in combination with spironolactone compared to untreated SNX at week 12 and was even lower than in SNX at week 8. In SNX + spironolactone it was significantly lower than in untreated SNX at week 12, but not different from SNX at week 8.
In SNX treated with dihydralazine glomerular volume was significantly higher than in SNX at week 8 and not different from untreated SNX at week 12.
The mean number of podocytes per glomerulus (table 2) was significantly lower in SNX at week 8 and decreased further significantly in untreated SNX at week 12. In SNX treated with losartan, spironolactone, and losartan + spironolactone respectively the number of podocytes per glomerulus did not differ from SNX at week 8 and was significantly higher compared to untreated SNX at week 12. In contrast the number of podocytes in SNX treated with dihydralazine was lower at week 12 than at week 8 and did not differ from untreated SNX.
The mean podocyte volume was significantly higher in SNX at week 8 and in untreated animals and was increased further at week 12. The podocyte volume in SNX treated with losartan alone or in combination with spironolactone was not different from that observed in SNX at week 8 and was significantly lower than in untreated SNX at week 12. In SNX treated with spironolactone alone at week 12 podocyte volume was higher than at week 8, but lower than in untreated SNX at week 12. Treatment with dihydralazine had no significant effect on mean podocyte volume .
The mean number of cells within the mesangium (table 2) (table 4) . This was prevented by treatment with losartan, spironolactone, or losartan + spironolactone, but not dihydralazine.
Western blotting
The expression of -smooth muscle actin ( SMA) in kidney tissue was significantly higher in untreated SNX (at week 8 and 12) compared to sham-op. It was significantly lower in SNX treated with spironolactone or losartan + spironolactone compared to untreated SNX at week 8 and 12 ( fig. 6 ).
The expression of TGF-1 in renal cortex was significantly higher in untreated SNX compared to sham-op. This was prevented in SNX treated with losartan, spironolactone, and losartan + spironolactone, but not in SNX treated with dihydralazine ( fig. 6 ).
Discussion
Our study documents that the regression of glomerulosclerosis achieved with losartan was not further augmented by adding non-hyperkalemic doses of spironolactone.
While spironolactone alone stopped progression of glomerulosclerosis, addition of spironolactone to losartan failed to cause further reversal of established glomerular changes.
The beneficial effects of AT1 and aldosterone blockade could not be reproduced by blood pressure lowering alone, using dihydralazine. We acknowledge, however, that the systemic blood pressure does not reflect the local intraglomerular pressure which contributes to glomerular damage.
Administration of aldosterone negates the renoprotective effect of ACE inhibition in both the stroke prone SHR (22) and in the renal ablation model (10) . A delayed increase of aldosterone concentration is seen in the serum of many patients receiving ACE inhibitors or AT1 blockers ("aldosterone breakthrough") (24). Aldosterone blockade was shown to slow the progression of podocyte damage and glomerulosclerosis in Dahl salt-hypertensive rats (19) . Our results showed that after high dose AT1 blockade adding a mineralocorticoid This finding is in line with the concept that increased angiotensin II signaling via the AT1 receptor in podocytes induces podocyte loss, glomerulosclerosis, and albuminuria (12) .
Podocytes have also been shown to be directly damaged by aldosterone (25) . In a past study mineralocorticoid receptor blockade protected against podocyte injury when started at the time of the insult (19) . Our results document preservation of podocyte number and lower number of desmin-positive podocytes even when the treatment is started late after kidney injury.
The reversal of glomerulosclerosis after inhibition of the renin-angiotensin system (RAS) involves restructuring of the glomerular capillary network (1). In vitro evidence showed that VEGF signaling between injured podocytes and glomerular endothelial cells was reduced and could be restored by AT1 blockade (14) . In agreement with this observation we detected less VEGF in injured glomeruli and this was restored to normal in animals treated with the AT1-R blocker. Furthermore spironolactone had similar effect on VEGF expression suggesting that aldosterone contributed to suppression of VEGF expression in glomeruli.
Albuminuria was significantly reduced by losartan either in monotherapy or in combination with spironolactone, but not by spironolactone, despite its protective effect on podocyte number and to a lesser extent on podocyte volume. This finding is in contrast to clinical observations (5, 23) . In an experimental nephrotic syndrome, however, mineralocorticoid receptor blockade reduced proteinuria when started immediately after the insult, but failed to reduce proteinuria when treatment was started later (20) .
Epithelial-to-mesenchymal transition, which was not directly assessed in the present study, plays a pivotal role in the progression of interstitial fibrosis and is induced by aldosterone (30) . One of its consequences is the de-novo expression of -smooth muscle actin ( SMA) in tubular epithelial cells (15) . Spironolactone caused regression of SMA in parallel with the prevention of further progression of the tubulointerstitial damage index and deposition of collagen IV.
The profibrotic effects of the activation of RAS are to a large extent mediated by the profibrogenic cytokine TGF- (28) . Interfering with TGF-signaling prevents renal damage (4). Our study documents by immunehistochemistry and Western blot that spironolactone suppressed TGF-expression, but did not amplify its suppression by losartan.
NF B-linked regulatory pathways has been demonstrated to mediate ANG IIdependent renal damage (17, 27) . In agreement with that observations regression of glomerulosclerosis was accompanied by downregulation of NF B.
In conclusion, in this short-term renal ablation model with no evidence of aldosterone breakthrough non-hyperkalemic doses of spironolactone -unlike similar lowering of blood pressure with dihydralazine -stopped progression of renal damage, specifically glomerular scarring and podocyte loss, but failed to amplify the protective effect of the AT 1 blocker losartan. 
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